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six assessments that resulted in conditional reimbursement were targeted therapies. 
Typically, with these targeted therapies, PFS or OS ranged from ~3 months to 9 
months with the cost-per-QALY > £45.000. Five of the six manufactures participated 
in a patient-access scheme which consisted of ﬁ xed-price discounts such as Cetuximab 
(CRC) and Geﬁ tinib (NSCLC) or performance schemes like sunitinib (GIST), Bortezo-
mib (myeloma), and Lenalidome (myeloma). CONCLUSIONS: Based on the retro-
spective analysis, it is clear that the biggest challenge for targeted-cancer therapies is 
affordability with only one of the targeted therapies receiving unconditional reim-
bursement. However, nearly all the other targeted therapies evaluated that offered >3 
months OS or PFS were recommended by NICE with a proviso to bring down the 
cost of treatment. Therefore, when companies develop their market access strategy, 
they should include a patient-access scheme in order to enter the UK market.
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OBJECTIVES: Achieving market access for new products has become complex for 
pharmaceutical companies. Faced with growing expenditure, health-care authorities 
accept or propose various schemes (risk sharing/payment for performance/commer-
cial): UK’s Department of Health coined a term Patient Access Scheme (PAS) and 
published speciﬁ c guidance for the industry. We performed an in-depth analysis of 
design of PASs in UK to revisit their typology and rationale. METHODS: We reviewed 
ofﬁ cial and grey literature on the Web sites of UK’s HTA Agency—NICE, the Depart-
ment of Health (DoH), the industry, and in the Internet. We searched for documents 
containing all synonimes of PAS and different scheme types. We selected PASs 
launched after 2006. RESULTS: We identiﬁ ed 13 PASs, all of which were designed/
implemented in consultation with NICE. Drug’s comparative effectiveness was central 
to the rationale behind the design of PASs. If effectiveness was acknowledged in the 
HTA, PAS was based on cost-containment (rituximab, erlotinib). If it was not recog-
nized, this was for one of the two reasons: (1) the uncertainity about the long-term 
effect of the drug, or (2) the value of ICER was questioned in the HTA. In case of 
(1), the PAS consisted in free provision of the drug by manufacturer after a predeﬁ ned 
period (lenalidomide, ranibizumab). In the case of (2), the PAS aimed at lowering the 
ICER either through cost containment (sunitinib, cetuximab, pemetrexed), through 
linking payment to outcomes (bortezomib, omalizumab), or by a mix of the two 
(certolizumab, ustekinumab). CONCLUSIONS: Formalized Health Technology 
Assessment is both a prerequisite and reason for implementing Patient Access Schemes 
in the UK. If the comparative effectiveness of a drug is acknowledged, the agreement 
is based on cost containment. On the other hand, if it is questioned, the PAS may 
have a form of a risk-sharing scheme and may be linking the payment to health 
outcomes (performance-based scheme).
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OBJECTIVES: Since its establishment, NICE has become increasingly explicit about 
the way it uses evidence on cost-effectiveness in decision-making—and, more recently, 
about the other factors it considers. This, together with other ways in which decision-
making has evolved, suggests a number of testable hypotheses. We propose and 
empirically test alternative ways that NICE decision-making might be modeled, build-
ing on and extending Devlin and Parkin (2004) and Dakin et al. (2006). The large 
number of NICE decisions now observable facilitates the use of more sophisticated 
modeling techniques. METHODS: NICE’s decisions are characterized as binary 
choices: yes or no to a technology in a speciﬁ cally deﬁ ned patient group or indication. 
NICE Guidance often contains multiple such decisions. The probability of NICE 
recommending a technology is modeled as depending on evidence on effectiveness and 
cost-effectiveness; characteristics of the patients, disease, or treatment; and contextual 
factors. Data were obtained from HTAinSite (http://www.htainsite.com) on November 
2009. RESULTS: Initial results, drawing on data for 262 decisions, suggest cost-
effectiveness alone explains the vast majority of NICE’s decisions, correctly classifying 
85%, with high sensitivity and speciﬁ city. The estimated threshold, around £40k, is 
higher than NICE’s stated threshold (20k–£30k) but similar to that estimated by 
Devlin and Parkin (2004). Results across alternative model speciﬁ cations showed that 
almost none of the other variables exert a statistically signiﬁ cant effect on decisions, 
with two exceptions. First, technologies for the treatment of cancer have a signiﬁ cantly 
higher probability of being accepted, ceteris paribus, implying a willingness to pay an 
additional >£10k per QALY gained by cancer patients. Second, analysis of the subset 
of decisions made after NICE’s second “social value judgement” document suggest an 
increased probability of rejection. CONCLUSIONS: This is work in progress; further 
results will be available to report from additional data extraction and modeling.
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OBJECTIVES: In the UK, Patient Access Schemes (PAS) have become more common 
in submissions to the National Institute for Health and Clinical Excellence (NICE). 
The increase in PAS is a result of the essential role such schemes play in enhancing 
the availability of high-cost treatments to payers. In published appraisals, minimal 
emphasis has been placed upon the administrative burden of PAS, which is typically 
described as “acceptable.” The aim of this study was to assess the impact of admin-
istering PAS in the UK, using both primary research and existing literature to identify 
key administrative challenges. METHODS: A literature search was conducted using 
PubMed and Google Scholar. Freedom of information requests were sent to NICE for 
data on PAS administration. a pilot questionnaire was distributed to all 19 contacts 
listed on the directory of NHS Chief Pharmacists in Wales, to assess the real-life 
burden of PAS administration. RESULTS: Limited literature is available on the admin-
istration of PAS. However, the literature search uncovered evidence that the admin-
istrative impact of PAS is being recognized. The creation of the Patient Access Scheme 
Liaison Unit (PASLU) in October 2009 and the publication of the Pharmaceutical 
Price Regulation Scheme (PPRS) are two such developments, both of which are steps 
toward a system that more accurately reﬂ ects the needs of NHS administrators. The 
return rate for the questionnaire was low; however, responders showed dissatisfaction 
with multiple aspects of PAS management. Responders emphasized the need to address 
NHS requirements (both ﬁ nancial and temporal) in order to facilitate accurate PAS 
administration. CONCLUSIONS: Encouraging steps have been taken to recognize the 
burden of PAS on the NHS; however, further research is required to assess whether 
these recent developments are meaningful in everyday practice. Additional support for 
appropriate PAS implementation must also be provided if these important schemes are 
to continue effectively. 
PODIUM SESSION III: BIASES, METHODOLOGICAL CHALLENGES, AND 
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BACKGROUND: Offering patients in oncology trials the opportunity to cross over 
to active treatment at disease progression is a commonly used strategy to address 
ethical issues associated with the use of placebo controls, but could lead to statistical 
challenges for the analysis of key end points such as overall survival. While an advan-
tage from the perspective of the treated patient enrolled in the trial, cross-over leads 
to loss of information and dilution of the comparative clinical efﬁ cacy and cost-
effectiveness results. OBJECTIVES: The purpose of the study is to compare alternative 
methods for analyzing overall survival data in the presence of cross-over, thus illustrat-
ing differences between methods, and providing guidance on choice of methodology. 
METHODS: Two promising methods for dealing with cross-over are inverse probabil-
ity of censoring weighting and the rank-preserving structural failure time model. The 
methods are compared with naïve censoring of data at cross-over and intention-to-
treat analysis ignoring cross-over using two recent examples of trials in oncology: the 
receptor tyrosine kinase inhibitor sunitinib in renal cell carcinoma (RCC) and in 
gastrointestinal stromal tumor (GIST). RESULTS: The analyses showed that for a trial 
with a low proportion of cross-over from placebo to active treatment (RCC), the 
choice of statistical method did not affect the results to a great extent; the range of 
relative mortality risk for active treatment versus control was narrow. With a high 
proportion of cross-over (GIST), the range of relative mortality risks was broader. 
CONCLUSIONS: Naïve censoring at cross-over can lead to bias and should be 
avoided. If cross-over occurs frequently, the inverse probability of censoring weighting 
method or the rank-preserving structural failure time model are recommended depend-
ing on the characteristics of cross over in the trial, trial size, and available data.
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BACKGROUND: Models are widely used in the cost-effectiveness analysis of health-
care interventions. Most models only simulate one patient cohort, but some use 
multiple cohorts. Advocates of multicohort modeling contend it better represents 
actual health-care implementation, especially where interventions are applied over 
speciﬁ c age ranges, as in cancer screening. When such an intervention is introduced, 
cohorts already older than the starting age only receive a partial intervention, possibly 
